Apimeds Pharmaceuticals US Inc
apimedsus.comWhat Do They Do?
Develops a bee-venom drug candidate for healthcare providers treating knee osteoarthritis pain and inflammation, with multiple sclerosis as a potential later use. Builds Bitcoin treasury infrastructure, yield programs, and validator services for corporations and institutions.
10-K for FY2025, filed May 4, 2026We are a clinical stage biopharmaceutical company in the process of developing Apitox, an intradermally administered bee venom-based toxin.…View ↗
The healthcare providers associated with the treatment of inflammation and pain management symptoms associated with OA and MS are not…View ↗
MindWave Innovations Inc (“MindWave,” the “Company,” “we,” “us” or “our”) is a technology platform company focused on institutional Digital…View ↗
We intend to commercialize our principal DAT offerings for institutional clients, which comprise: (i) secure corporate Bitcoin treasury…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed May 4, 2026
Who Are Their Customers?
Healthcare providers involved in osteoarthritis and multiple sclerosis care are potential customers for Apitox. The Bitcoin platform targets corporate treasury teams and institutional investors, plus financial intermediaries and organizations with significant Bitcoin holdings; it plans direct enterprise sales and channels through custodians, wallet providers, and financial institutions.
10-K for FY2025, filed May 4, 2026The healthcare providers associated with the treatment of inflammation and pain management symptoms associated with OA and MS are not…View ↗
We target enterprise clients that require institutional governance, custody segregation, and audit-ready reporting for Bitcoin treasury…View ↗
We plan to distribute our DAT solutions directly to enterprise clients through internal business development and relationship management…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$20.2MView ↗
- ▲ +658% (Loss)
- vs −$2.7M in Q2 FY2025
-
Aug 21, 2026
FreeT transferred Apitox-related rights to the company
The transferred package includes Korean clinic-market rights and royalty and overseas proceeds interests tied to Apitox.
Sources
8-K, filed Aug 21, 2026
Pursuant to the Assignment Agreement, FreeT irrevocably assigned, transferred, conveyed and delivered to the Company all of FreeT’s right…View ↗
-
May 5, 2026
Sungjoon Chae was appointed Co-Chief Executive Officer
Sources
8-K, filed May 5, 2026
On May 4, 2026, pursuant to a nomination by a stockholder of Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “Company”), the…View ↗
Loading...
